Fairvalue-Calculator Fairvalue-Calculator
EN DE

Century Therapeutics, Inc (IPSC) Fair Value & Analysis

Healthcare · US · Market cap $413M

Price$2.41
Fair Value$3.97
Upside+64.7%
Quality95/100
Evidence: Low Range $2.97 – $4.96

Fair value as of: Jun 24, 2026

Analysis

Century Therapeutics, Inc (IPSC) currently trades at $2.41, while our model-based Fair Value estimate is $3.97 — implying the stock looks roughly 64.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Century Therapeutics, Inc (IPSC) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $3.97 versus a price of $2.41 — about +65% (undervalued). Model-based estimate, not financial advice.
What is the fair value of IPSC?
Our 21-model fair value for Century Therapeutics, Inc is $3.97 (as of Jun 24, 2026), built from audited fundamentals. The current price is $2.41.
What is the quality score of IPSC?
Century Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.